2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5686 GPRC5D participates in adhesion-mediated drug resistance and UPR dysregulation in multiple myeloma

Mei Zou, Chenggong Li2, Jia Xu3, Wenjing Luo4, Mengyi Du5, Haiming Kou6, Qiuzhe Wei7, Qiaolin Liu8, Wanying Zhang, PhD9, Peiru Li10, Heng Mei, MD, PhD11
1 Hubei Clinical Medical Research Center for Cellular Therapy of Tumor Diseases, Wuhan, China, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Hubei Clinical Medical Research Center for Cellular Therapy of Tumor Diseases, Wuhan, China, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Hubei Clinical Medical Research Center for Cellular Therapy of Tumor Diseases, Wuhan, China, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
5 Hubei Clinical Medical Research Center for Cellular Therapy of Tumor Diseases, Wuhan, China, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Hubei Clinical Medical Research Center for Cellular Therapy of Tumor Diseases, Wuhan, China, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: GPRC5D is an emerging immunotherapeutic target in multiple myeloma (MM), yet its pathophysiological role in MM cells remains poorly understood. Through systematic analysis of nearly 50 MM GSE datasets, we found GPRC5D significantly upregulated in PI-resistant (1.565-fold) and iMID-resistant (1.311-fold) subgroups versus sensitive counterparts, suggesting its potential role in drug resistance. However, the functional contribution of GPRC5D to MM drug resistance and the underlying mechanisms are completely unknown. We therefore sought to define the role of GPRC5D in MM drug resistance and elucidate its molecular basis.

Methods: We generated GPRC5D-overexpressing (8226-OE, U266-OE) and knockdown (MM1S-KD, OPM2-KD, H929-KD) MM cell lines via lentiviral transduction. Cell proliferation, cell cycle, and apoptosis were assessed by CCK-8 and flow cytometry. Drug sensitivity to bortezomib, lenalidomide, and their combination was evaluated. Fibronectin, collagen, integrin, and BMSC monolayers were added to explore their effects on drug resistance. RNA-seq and qPCR were used to profile transcriptional changes. CD138+ myeloma cells were purified from newly diagnosed MM patients to investigate the effects of GPRC5D expression in primary cell drug sensitivity.

Results: GPRC5D overexpression or knockdown did not affect cell proliferation, cell cycle, or apoptosis. Strikingly, upon drug treatment, GPRC5D-overexpressing cells exhibited significantly higher survival compared to controls, while knockdown cells showed reduced survival. This survival advantage was specifically preserved when cells were cultured on fibronectin, but not on collagen or integrin substrates, implicating fibronectin-mediated adhesion as a critical context for GPRC5D-driven resistance. Mechanistically, RNA-seq revealed that GPRC5D overexpression coordinately activated PI3K/MAPK/NF-κB/Wnt/Notch signaling cascades and induced UPR imbalance, characterized by upregulation of HSPA5 and downregulation of DDIT3.In primary CD138+ MM cells from newly diagnosed patients, we confirmed that higher GPRC5D expression correlated with significantly increased ex vivo drug resistance.

Conclusions: Our study identifies GPRC5D as a previously unrecognized mediator of fibronectin-adhesion-driven drug resistance in MM, functioning through coordinate activation of multiple survival pathways and UPR dysregulation. The convergent evidence from cell lines, patient datasets, and primary patient samples positions GPRC5D as a promising therapeutic target, and its combination with PI/iMID-based regimens may represent a novel strategy to overcome drug resistance in MM.

Mei Zou: No relevant conflicts of interest to declare.